An interventional study of Osprey IV and Historical Controls in Vascular Access Device Complications and Catheterization, Peripheral, sponsored by Community Medical Center, Toms River, NJ. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Community Medical Center, Toms River, NJ · Not applicable, Interventional, and Treatment
Device manufacturer withdrew support
Emergency Department Patients who were to get intravenous (IV) access through routine medical care will receive it through trademarked catheter via convenience sample. Patient and clinician experience, including adverse events, will be recorded. A standardized data entry sheet will be collected at time of enrollment, and then daily thereafter while the subject has the IV. The data collected will remain anonymous.
Identification of Subjects:
The emergency department is a designated participating unit providing subjects with medical care that are anticipated to be placed in the observation unit or admitted to an inpatient unit. Subjects who meet inclusion criteria will be consented to be included in the study.
Assignment of Subject Identification Number:
A unique identification number will be given to study subjects. Subject numbers will be assigned in sequential order. The subject number will consist of 6 characters. The first three characters will designate the manufacturer-specific protocol number (SVI). The last three characters will designate the subject by number in sequential order.
Informed Consent:
The nurse trained in placing this device will first consent the patient with written forms provided. All protocol nurses trained in this device will also have completed CITI training courses per our institutional guidelines.
Treatment Assignment:
Within this single arm study, subjects will be assigned to the study in a single treatment group. All patients in the convenience sample who would have received a standard stocked intravenous catheter will instead receive an Osprey catheter provided by the manufacturer. They will be compared against historical controls. Historical controls will be collected from a review of relevant literature, which has been determined to be stable across time and region.
Data Collection Method A Case Report Form (CRF) will be utilized to collect insertion related study data. The CRF will not include any patient identifying information such as name or medical identification number. The subject's demographic (age, race, and gender); baseline information (comorbidities); type of medications/fluids delivered will be documented from already captured Epic documentation.
A second Case Report Form (CRF) will be utilized to collect device performance study data. The CRF will not include any patient identifying information such as name or medical identification number. Device condition (ability to flush and obtain a blood return), Site condition (presence of redness, edema, drainage), patient response (level of pain) and dwell time will be extracted from Epic as this is the current standard practice to do so.
Active patients in the study will be maintained in a file on a secure drive that study personnel have to refer to to follow up active patients. Once active patients are no longer being followed daily, their name will be removed from that file. CRF forms will be filled out by hand and secured in a locked box. The data from both CRFs will be transcribed into a digital worksheet i.e. Microsoft Excel, which will be stored on a secured network drive maintained by the hospital.
Study Procedure Subjects will be admitted into the study according to the aforementioned criteria.
Hospital protocols will be followed for placement of the PIV. The site will be marked with date, time and initials of inserter. During and immediately after the IV placement procedure, the CRF will be initiated by staff associated with this study. If unsuccessful with first attempt at PIV placement, an attempt at another site with the same technique and device will be performed. This will be repeated according to facility policy and procedure until a successful PIV is in place or the physician decides to use an alternative therapy that no longer requires peripheral access. All catheters will be stabilized using the same form of stabilization device for uniformity in securement procedure throughout the duration of the study.
Daily assessments will occur per facility policy and procedure. An assessment will include; any level of pain and/or tenderness; presence of erythema; edema; induration; leakage of fluid or purulent drainage from the puncture site; catheter dysfunction (eg, resistance when flushing, absence of a blood return. Daily assessment will continue until the device is removed, completion of therapy or discharge. Once all the required data is collected, all de-identified data will be entered as a "data set" into the post procedure CRF for management/analysis. The final paper CRF will be placed in a study folder and maintained for record keeping and data analysis.
Community Medical Center, Toms River, NJ is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria i. Any gender, 18 years of age or older ii. Acceptable candidate for an elective PIV as determined by physician. iii. Anticipated admission to inpatient unit.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects enrolled will receive the study device as part of their routine medical care.
Device: Osprey IV · Other: Historical Controls
Utilization of novel needle over catheter commercial insertion device
Outcome rates from catheter over needle devices (traditional manner of inserting peripheral IV)
Number of Attempts
The number of attempts that operator needs to access vein and secure device for proper bidirectional flow
Time frame: 10 minutes
Blood culture contamination rates
Proportion of blood culture specimens (when drawn) that are reported with contaminants
Time frame: 1 week
Flushing characteristic
whether operator finds flow into patient to be impeded or unimpeded
Time frame: 10 minutes
Patient discomfort
Patient's self assessment of level of pain experienced by insertion
Time frame: 10 minutes
Time to removal
Total days device remained in place
Time frame: 1 week
Removal reason
If removed for device failure vs cessation of therapy
Time frame: 1 week
Edema
Presence of edema
Time frame: 1 week
Redness
Presence of redness
Time frame: 1 week
Drainage
Presence of drainage
Time frame: 1 week
Site Pain
Presence of site pain
Time frame: 1 week
Plan to share: No
Device manufacturer withdrew support
Device manufacturer withdrew support
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Community Medical Center, Toms River, NJ